Article
Clinical Neurology
Izanne Roos, Charles Malpas, Emmanuelle Leray, Romain Casey, Dana Horakova, Eva Kubala Havrdova, Marc Debouverie, Francesco Patti, Jerome De Seze, Guillermo Izquierdo, Sara Eichau, Gilles Edan, Alexandre Prat, Marc Girard, Serkan Ozakbas, Pierre Grammond, Helene Zephir, Jonathan Ciron, Elisabeth Maillart, Thibault Moreau, Maria Pia Amato, Pierre Labauge, Raed Alroughani, Katherine Buzzard, Olga Skibina, Murat Terzi, David Axel Laplaud, Eric Berger, Francois Grand'Maison, Christine Lebrun-Frenay, Elisabetta Cartechini, Cavit Boz, Jeannette Lechner-Scott, Pierre Clavelou, Bruno Stankoff, Julie Prevost, Ludwig Kappos, Jean Pelletier, Vahid Shaygannejad, Bassem Yamout, Samia J. Khoury, Oliver Gerlach, Daniele L. A. Spitaleri, Vincent Van Pesch, Olivier Gout, Recai Turkoglu, Olivier Heinzlef, Eric Thouvenot, Pamela Ann McCombe, Aysun Soysal, Bertrand Bourre, Mark Slee, Tamara Castillo-Trivino, Serge Bakchine, Radek Ampapa, Ernest Gerard Butler, Abir Wahab, Richard A. Macdonell, Eduardo Aguera-Morales, Philippe Cabre, Nasr Haifa Ben, Anneke Van der Walt, Guy Laureys, Liesbeth Van Hijfte, Cristina M. Ramo-Tello, Nicolas Maubeuge, Suzanne Hodgkinson, Jose Luis Sanchez-Menoyo, Michael H. Barnett, Celine Labeyrie, Steve Vucic, Youssef Sidhom, Riadh Gouider, Tunde Csepany, Javier Sotoca, Koen de Gans, Abdullah Al-Asmi, Yara Dadalti Fragoso, Sandra Vukusic, Helmut Butzkueven, Tomas Kalincik
Summary: This study evaluated the rate of disease reactivation after cessation of multiple sclerosis (MS) disease-modifying therapy. The results showed that the rate of relapse varied among different treatments and recommencement of a subsequent therapy reduced the risk of disease activity.
Article
Immunology
Vinicius O. Boldrini, Ana M. Marques, Raphael P. S. Quintiliano, Adriel S. Moraes, Carla R. A. V. Stella, Ana Leda F. Longhini, Irene Santos, Marilia Andrade, Breno Ferrari, Alfredo Damasceno, Rafael P. D. Carneiro, Carlos Otavio Brandao, Alessandro S. Farias, Leonilda M. B. Santos
Summary: This study found that CD19(+) B cells in the peripheral blood of multiple sclerosis (MS) patients may express serine-protease granzyme-B (GzmB), resembling cytotoxic CD8(+) T lymphocytes. This finding may provide important clues for investigating the pathogenesis of MS and for the development of new therapeutic interventions.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Clinical Neurology
Simone Hjaeresen, Tobias Sejbaek, Markus Axelsson, Sif Klovedal Mortensen, Helle Vinslov-Jensen, Gorm Pihl-Jensen, Lenka Novakova, Christian Bonde Pedersen, Bo Halle, Frantz Rom Poulsen, Mengliang Zhang, Eirikur Benedikz, Jette Lautrup Frederiksen, Jan Lycke, Zsolt Illes, Asa Fex-Svenningsen
Summary: The levels of macrophage migration inhibitory factor (MIF) in the cerebrospinal fluid (CSF) of patients with different subtypes of multiple sclerosis (MS) were investigated. MIF levels were found to be affected by gender and disease type. MIF levels were decreased in clinically isolated syndrome (CIS) and relapsing-remitting MS (RRMS) patients, but elevated in secondary progressive MS (SPMS) patients. The expression of MIF in the human brain was localized to neurons, astrocytes, pericytes, and oligodendrocytes.
JOURNAL OF THE NEUROLOGICAL SCIENCES
(2022)
Article
Clinical Neurology
Claire Bridel, Cyra E. Leurs, Zoe Y. G. J. van Lierop, Zoe L. E. van Kempen, Iris Dekker, Harry A. M. Twaalfhoven, Bastiaan Moraal, Frederik Barkhof, Bernard M. J. Uitdehaag, Joep Killestein, Charlotte E. Teunissen
Summary: This study investigated the potential of serum neurofilament light (NfL) to reflect or predict progression in RRMS patients treated with natalizumab, finding that NfL fails to capture or predict progression largely independently of acute inflammatory disease activity. Additional biomarkers may be needed to monitor progression in these patients.
Article
Clinical Neurology
Lenka Novakova, Marcus Henricsson, Elias Bjornson, Markus Axelsson, Jan Boren, Igal Rosenstein, Jan Lycke, Susanna L. Cardell, Maria Blomqvist
Summary: The diagnostic utility of cerebrospinal fluid (CSF) sulfatide isoform levels in different courses or phenotypes of multiple sclerosis (MS) was investigated. The results showed that there was no difference in CSF total sulfatide concentrations and isoform distribution among the study groups, and the levels were independent of disease course/phenotype, disease duration, time to conversion to secondary progressive MS, age, and disability.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2023)
Article
Clinical Neurology
Cavit Boz, Serkan Ozakbas, Murat Terzi, Rana Karabudak, Serhan Sevim, Recai Turkoglu, Aysun Soysal, Belgin Petek Balci, Husnu Efendi, Omer Faruk Turan, Nur Yuceyar, Mehmet Fatih Yetkin, Serap Zengin Karahan, Meltem Demirkiran, Sibel Guler, Kadriye Agan, Nefati Kiylioglu, Cavid Baba, Asli Tuncer, Mesrure Koseoglu
Summary: This study compared the efficacy of three drugs (fingolimod, natalizumab, and ocrelizumab) in reducing disease activity in RRMS. The results showed that natalizumab and ocrelizumab had similar effects on relapse control, and both were better than fingolimod. The three therapies had similar effects on disability outcomes.
NEUROLOGICAL SCIENCES
(2023)
Letter
Clinical Neurology
Harald Kropshofer, Dieter A. Haering, Ludwig Kappos, David Leppert, Jens Kuhle
Summary: The results of this study contradict with earlier large phase 3 studies, suggesting that high baseline serum neurofilament light chain levels are associated with increased risk of disability progression in MS. The authors hypothesize that this discrepancy may be due to the anti-inflammatory effects of natalizumab, which suppresses inflammatory activity and renders sNfL unrelated to disability progression.
Article
Immunology
Igal Rosenstein, Sofia Rasch, Markus Axelsson, Lenka Novakova, Kaj Blennow, Henrik Zetterberg, Jan Lycke
Summary: This study suggests that determination of intrathecal immunoglobulin M synthesis (ITMS) and neurofilament light concentration in cerebrospinal fluid (CSF) can be useful biomarkers for predicting disease severity and disability in relapsing-remitting multiple sclerosis (RRMS). The combination of ITMS with CSF neurofilament light (cNfL) shows a stronger predictive value.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, Research & Experimental
Jai Perumal, Roumen Balabanov, Ray Su, Roger Chang, Laura Balcer, Steven Galetta, Denise I. Campagnolo, Robin Avila, Lily Lee, Danette Rutledge, Robert J. Fox
Summary: The STRIVE study demonstrates that natalizumab treatment is effective in reducing disease activity in early relapsing-remitting multiple sclerosis patients, with good long-term safety and efficacy. Baseline factors such as age and brain MRI abnormalities can predict whether patients will achieve no evidence of disease activity status.
ADVANCES IN THERAPY
(2021)
Article
Clinical Neurology
S. Grahl, M. Bussas, B. Wiestler, P. Eichinger, C. Gaser, J. Kirschke, C. Zimmer, A. Berthele, B. Hemmer, M. Muehlau
Summary: This study compared the effects of Fingolimod and Natalizumab in treating relapsing-remitting multiple sclerosis, finding that Fingolimod treatment led to more new white matter lesions but lower overall brain atrophy. The results support the notion that Fingolimod has stronger neuroprotective properties compared to Natalizumab.
Article
Neurosciences
Qing Xia, XinYu Yang, JiaBin Shi, ZiJie Liu, YaHui Peng, WenJing Wang, BoWen Li, Yu Zhao, JiaYing Xiao, Lei Huang, DaYong Wang, Xu Gao
Summary: Alzheimer's disease is a neurodegenerative disorder characterized by abnormal accumulation of amyloid beta peptides and Tau protein in the brain. Mutations in amyloid precursor protein gene can cause familial Alzheimer's disease, but the A673T mutation shows protective effects against it.
MOLECULAR NEUROBIOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Damien D. Pearse, Andrew B. Hefley, Alejo A. Morales, Mousumi Ghosh
Summary: This study investigated the expression of transglutaminase-2 (TG2) in brain tissue of multiple sclerosis (MS) patients and its correlation with binding partners and effectors involved in inflammation, scar formation, and repair antagonism. The results showed that TG2 was upregulated in active lesions and colocalized with astrocytes and extracellular matrix components.
Article
Neurosciences
Maria-Eleftheria Evangelopoulos, Georgios Koutsis, Fotini Boufidou, Manolis Markianos
Summary: Cholesterol levels may be associated with disease characteristics in multiple sclerosis, particularly with demyelination and immune response. This study found lower levels of plasma and cerebrospinal fluid cholesterol in patients with multiple sclerosis. Patients with positive oligoclonal bands had even lower cerebrospinal fluid cholesterol levels, which may be related to disease progression and enhanced humoral immune response.
NEUROBIOLOGY OF DISEASE
(2022)
Review
Biochemistry & Molecular Biology
Sylwia Pietrasik, Angela Dziedzic, Elzbieta Miller, Michal Starosta, Joanna Saluk-Bijak
Summary: Multiple sclerosis is a neurodegenerative disease with a variable course, often characterized by alternating periods of exacerbation and stabilization. Distinguishing between subtypes early can lead to faster implementation of appropriate treatment. Research suggests circulating microRNAs may be valuable for MS diagnosis and predicting disease subtype.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Clinical Neurology
Fabien Rollot, Justine Couturier, Romain Casey, Sandrine Wiertlewski, Marc Debouverie, Jean Pelletier, Jerome De Seze, Pierre Labauge, Aurelie Ruet, Eric Thouvenot, Jonathan Ciron, Eric Berger, Olivier Gout, Pierre Clavelou, Bruno Stankoff, Olivier Casez, Bertrand Bourre, Helene Zephir, Thibault Moreau, Christine Lebrun-Frenay, Elisabeth Maillart, Gilles Edan, Jean-Philippe Neau, Alexis Montcuquet, Philippe Cabre, Jean-Philippe Camdessanche, Gilles Defer, Haifa Ben Nasr, Aude Maurousset, Karolina Hankiewicz, Corinne Pottier, Emmanuelle Leray, Sandra Vukusic, David-Axel Laplaud
Summary: This study compared the effectiveness of NTZ and anti-CD20 as a switch for FNG in highly active RRMS patients in France. The results showed no difference between the two treatments regarding the first occurrence of relapse, EDSS worsening, and MRI activity. However, there was a higher risk of treatment discontinuation with NTZ compared to anti-CD20.
Article
Clinical Neurology
Igal Rosenstein, Markus Axelsson, Lenka Novakova, Kaj Blennow, Henrik Zetterberg, Jan Lycke
Summary: This study validates the utility of cerebrospinal fluid NFL (cNFL) as a biomarker in clinical practice of relapsing-remitting multiple sclerosis (RRMS). cNFL can reliably diagnose disease activity, predict treatment response, disability, and conversion from RRMS to SPMS, suggesting its inclusion in the assessment of patients at MS onset.
MULTIPLE SCLEROSIS JOURNAL
(2022)
Editorial Material
Clinical Neurology
Jan Lycke, Anders Svenningsson
MULTIPLE SCLEROSIS JOURNAL
(2022)
Article
Clinical Neurology
Magnus Johnsson, Helen H. Farman, Kaj Blennow, Henrik Zetterberg, Clas Malmestrom, Markus Axelsson, Jan Lycke
Summary: This study investigated the effect of extending the dosing interval of natalizumab (NZ) from 4 to 6 weeks on serum neurofilament light chain (sNfL) concentrations in patients with relapsing-remitting multiple sclerosis (RRMS). The results showed that extending the NZ dosing interval did not increase axonal damage in patients with RRMS, as determined with sNfL.
MULTIPLE SCLEROSIS JOURNAL
(2022)
Article
Clinical Neurology
Magnus Johnsson, Fredrik Asztely, Susanne Hejnebo, Markus Axelsson, Clas Malmestrom, Torbjorn Olausson, Jan Lycke
Summary: SARS-COV-2 infection can result in MOGAD, but there is no evidence of cross-reactive immune response between the virus and MOG.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY
(2022)
Article
Clinical Neurology
Colin Groot, Ruben Smith, Erik Stomrud, Alexa Pichet Binette, Antoine Leuzy, Anika Wuestefeld, Laura E. M. Wisse, Sebastian Palmqvist, Niklas Mattsson-Carlgren, Shorena Janelidze, Olof Strandberg, Rik Ossenkoppele, Oskar Hansson
Summary: Among amyloid-positive individuals, tau discordance predicts increased rates of tau accumulation on PET, but not increased cognitive decline or cortical thinning. Individuals with this biomarker profile may be an interesting target group for intervention in early Alzheimer's disease.
Article
Clinical Neurology
Sonja Kosek, Barbro Persson, Rui Rodrigues, Clas Malmestrom, Anna Rostedt Punga, Joachim Burman
Summary: This study aimed to estimate the 5-year incidence rate of autoimmune encephalitis (AE) and paraneoplastic neurological syndrome (PNS) in Sweden. The results showed that the incidence rate of AE and PNS doubled from 2015 to 2019.
ACTA NEUROLOGICA SCANDINAVICA
(2023)
Editorial Material
Clinical Neurology
Niklas Mattsson-Carlgren, Sebastian Palmqvist
Article
Medicine, Research & Experimental
Gemma Salvado, Rik Ossenkoppele, Nicholas J. Ashton, Thomas G. Beach, Geidy E. Serrano, Eric M. Reiman, Henrik Zetterberg, Niklas Mattsson-Carlgren, Shorena Janelidze, Kaj Blennow, Oskar Hansson
Summary: Several promising plasma biomarkers for Alzheimer's disease have been developed, but their neuropathological correlates are not fully understood. This study investigates the associations between multiple plasma biomarkers and amyloid and tau neuropathological measures. The results suggest that plasma p-tau217 and A beta 42/40 might be an optimal combination for assessing Alzheimer's-related pathology.
EMBO MOLECULAR MEDICINE
(2023)
Article
Clinical Neurology
Ali Manouchehrinia, Hanna Larsson, Mohammad Ehsanul Karim, Jan Lycke, Tomas Olsson, Ingrid Kockum
Summary: About 40%-70% of individuals with multiple sclerosis (MS) experience cognitive impairment. This study aimed to compare the effectiveness of natalizumab with other disease-modifying treatments (DMTs) in improving cognition. The analysis of Swedish nationwide surveillance data revealed that natalizumab-treated individuals had a higher likelihood of cognitive improvement compared to those treated with other DMTs.
MULTIPLE SCLEROSIS JOURNAL
(2023)
Article
Clinical Neurology
Eske Christiane Gertje, Shorena Janelidze, Danielle van Westen, Nicholas Cullen, Erik Stomrud, Sebastian Palmqvist, Oskar Hansson, Niklas Mattsson-Carlgren
Summary: There is an association between white matter lesions (WML) and CSF biomarkers of neuroinflammation in individuals without dementia. Especially, PlGF is associated with WML independent of Aβ status and cognitive impairment.
Article
Clinical Neurology
Sofia Sandgren, Lenka Novakova, Markus Axelsson, Firoozeh Amirbeagi, Ingrid Kockum, Tomas Olsson, Clas Malmestrom, Jan Lycke
Summary: A study in Sweden found that monitoring autoimmune antibodies, particularly thyroid autoantibodies, can predict the risk of secondary autoimmune diseases caused by Alemtuzumab treatment. The presence of thyroid autoantibodies increased the risk of developing autoimmune thyroid disease (AITD) by 50%.
FRONTIERS IN NEUROLOGY
(2023)
Article
Clinical Neurology
Elin Dybjer, Atul Kumar, Katarina Nagga, Gunnar Engstrom, Niklas Mattsson-Carlgren, Peter M. Nilsson, Olle Melander, Oskar Hansson
Summary: Dybjer et al. found that the polygenic risk of type 2 diabetes is associated with the risk of dementia, especially vascular dementia. However, further analysis did not support a causal relationship between type 2 diabetes and vascular dementia. It is still unclear whether the genetic risk markers for type 2 diabetes and dementia are the same or if there is a causal link between the two diseases.
BRAIN COMMUNICATIONS
(2023)
Article
Clinical Neurology
Erin M. Jonaitis, Shorena Janelidze, Karly A. Cody, Rebecca Langhough, Lianlian Du, Nathaniel A. Chin, Niklas Mattsson-Carlgren, Kirk J. Hogan, Bradley T. Christian, Tobey J. Betthauser, Oskar Hansson, Sterling C. Johnson
Summary: An accurate blood test for early detection of Alzheimer's disease is important for secondary prevention. In this study, plasma phosphorylated tau 217 (pTau(217)) was found to be strongly related to amyloid and tau PET markers, and could predict longitudinal cognitive performance.
BRAIN COMMUNICATIONS
(2023)
Article
Clinical Neurology
Elisa Longinetti, Simon Englund, Joachim Burman, Katharina Fink, Anna Fogdell-Hahn, Martin Gunnarsson, Jan Hillert, Annette Magdalene Langer-Gould, Jan Lycke, Petra Nilsson, Jonatan Salzer, Anders Svenningsson, Johan Mellergard, Tomas Olsson, Fredrik Piehl, Thomas Frisell
Summary: This study analyzed a Swedish nationwide observational study on RRMS to identify trajectories of processing speed and physical disability after DMT start. The results showed that patients' processing speed remained stable over time, while those with moderate physical disability experienced deterioration in physical function. However, there was a strong association between processing speed and disability.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2023)